2019 Looks Bright, SD-101 should send stocks soaring
Dynavax recently presented a company outlook for 2019 at the JP Morgan Healthcare Conference. During the presentation, CEO Eddie Gray revealed encouraging HEPISLAV-B sales for Q4 of ~$3.7M.
2018 was a big year for Dynavax's lead immuno-oncology candidate SD-101. The company has stated they are looking for a potential partner for their planned Phase III in melanoma.
The stock experienced a strong sell-off in Q4, but the new year should treat DVAX well.
In its March 2019 Cowen presentation, Dynavax issued a pipeline slide. Although I note a lack of phase 3 candidates. It has but a single therapy, SD-101, in phase 2 that it is advancing in combination with Merck's Keytruda (pembrolizumab) in various combinations.
Positive news from SD-101 should send stocks soaring.
2018 was a big year for Dynavax's lead immuno-oncology candidate SD-101. The company has stated they are looking for a potential partner for their planned Phase III in melanoma.
The stock experienced a strong sell-off in Q4, but the new year should treat DVAX well.
In its March 2019 Cowen presentation, Dynavax issued a pipeline slide. Although I note a lack of phase 3 candidates. It has but a single therapy, SD-101, in phase 2 that it is advancing in combination with Merck's Keytruda (pembrolizumab) in various combinations.
Positive news from SD-101 should send stocks soaring.